Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Indian Journal of Pharmacology
|
September 9, 2024
Advancing pediatric drug development in South Asia: Current landscape and vision for the future
Rajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, et al.
Clinical Pharmacology in Drug Development
|
June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Daryl J Fediuk, Kyle Matschke, Yali Liang, et al.
British Journal of Clinical Pharmacology
|
January 17, 2012
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Rajesh Krishna, Daria Stypinski, Melissa Ali, et al.
Biopharmaceutics & Drug Disposition
|
October 28, 2011
Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
Rajesh Krishna, Daria Stypinski, Melissa Ali, et al.
Journal of Clinical Pharmacology
|
July 16, 2009
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects
Daniel M Bloomfield, Rajesh Krishna, David Hreniuk, et al.
Biopharmaceutics & Drug Disposition
|
June 16, 2007
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman, Goutam C Mistry, Wen-Lin Luo, et al.
Journal of Clinical Pharmacology
|
November 14, 2008
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers
Rajesh Krishna, Arthur J Bergman, Bo Jin, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Ira Gantz, Ngozi Erondu, Madhuja Mallick, et al.
Advances in Therapy
|
June 8, 2021
Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
Hanjing Chen, Weili Chen, Hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Indian Journal of Pharmacology
|
September 9, 2024
Advancing pediatric drug development in South Asia: Current landscape and vision for the future
Rajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, et al.
Clinical Pharmacology in Drug Development
|
June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Daryl J Fediuk, Kyle Matschke, Yali Liang, et al.
British Journal of Clinical Pharmacology
|
January 17, 2012
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Rajesh Krishna, Daria Stypinski, Melissa Ali, et al.
Biopharmaceutics & Drug Disposition
|
October 28, 2011
Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
Rajesh Krishna, Daria Stypinski, Melissa Ali, et al.
Journal of Clinical Pharmacology
|
July 16, 2009
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects
Daniel M Bloomfield, Rajesh Krishna, David Hreniuk, et al.
Biopharmaceutics & Drug Disposition
|
June 16, 2007
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman, Goutam C Mistry, Wen-Lin Luo, et al.
Journal of Clinical Pharmacology
|
November 14, 2008
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers
Rajesh Krishna, Arthur J Bergman, Bo Jin, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Ira Gantz, Ngozi Erondu, Madhuja Mallick, et al.
Advances in Therapy
|
June 8, 2021
Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
Hanjing Chen, Weili Chen, Hui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
Page
of 10